DRCT(DRCT)
DRCT
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $34M | $39M |
| Low | $34M | $39M |
| High | $34M | $39M |
| EBITDA Avg | $-3M | $-4M |
| Low | $-3M | $-4M |
| High | $-3M | $-4M |
| EBIT Avg | $-5M | $-5M |
| Low | $-5M | $-5M |
| High | $-5M | $-5M |
| Net Income Avg | $-10M | $-2M |
| Low | $-10M | $-2M |
| High | $-10M | $-2M |
| EPS Avg | $-32.34 | $-5.15 |
| Low | $-32.34 | $-5.15 |
| High | $-32.34 | $-5.15 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 |
|---|---|---|
| Revenue Avg | $9M | $10M |
| Low | $9M | $10M |
| High | $9M | $10M |
| EBITDA Avg | $-865,856 | $-889,774 |
| Low | $-865,856 | $-889,774 |
| High | $-865,856 | $-889,774 |
| EBIT Avg | $-1M | $-1M |
| Low | $-1M | $-1M |
| High | $-1M | $-1M |
| Net Income Avg | $-5M | $-5M |
| Low | $-5M | $-5M |
| High | $-5M | $-5M |
| EPS Avg | $-9.02 | $-8.64 |
| Low | $-9.02 | $-8.64 |
| High | $-9.02 | $-8.64 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |